Posted by Michael Wonder on 28 Oct 2021
NICE publishes final guidance for Janssen's apalutamide
28 October 2021 - Final guidance for two indications.
Apalutamide plus androgen deprivation therapy is recommended, within its marketing authorisation, as an option for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults. High risk is defined as a blood prostate-specific antigen level that has doubled in 10 months or less on continuous androgen deprivation therapy (TA740).
Apalutamide plus androgen deprivation therapy is recommended as an option for treating hormone-sensitive metastatic prostate cancer in certain adults (TA741).
